+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Down Syndrome - Epidemiology Forecast-2027

  • ID: 4661510
  • Report
  • October 2018
  • Region: Global
  • 120 pages
  • DelveInsight
1 of 2
‘Down Syndrome - Epidemiology Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Down Syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Down syndrome - Disease Understanding and Treatment Algorithm

The Down Syndrome market report gives the thorough understanding of the Down syndrome by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Down syndrome in the US, Europe, and Japan.

Down syndrome Epidemiology

The Down syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by gender- specific [Male and Female] and type specific [Trisomy 21, Mosaicism and Translocation] and diagnosed prevalent population of Down syndrome by clinical manifestation (Congenital heart disease, Ophalmologic complication, Neurological disorder, Hematologic - transient myeloproliferative disorder, Gastro intestinal, Otolaryngology, Endocrinlogy and Others).

According to this research, the prevalent cases of Down syndrome was 541,538 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of Down syndrome with 258,502 prevalent cases in 2016. In 7MM, males had highest prevalent cases of DS as compared to females in 2016. This trend is expected to increase during the study period

Down syndrome Epidemiology Segmentation

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

The disease epidemiology covered in the report is segmented by gender- specific [Male and Female] and type specific [Trisomy 21, Mosaicism and Translocation] and diagnosed prevalent population of Down syndrome by clinical manifestation (Congenital heart disease, Ophalmologic complication, Neurological disorder, Hematologic - transient myeloproliferative disorder, Gastro intestinal, Otolaryngology, Endocrinlogy and Others).

Report Scope
  • The report covers detailed overview of Down syndrome explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of Down syndrome
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by gender, sub-types and diagnosed prevalent population of Down syndrome by clinical manifestation in 7MM
Down syndrome Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Down syndrome Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Keys Competition
Down syndrome Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the Down syndrome market
  • Organize sales and marketing efforts by identifying the best opportunities for Down syndrome market
  • To understand the future market competition in the Down syndrome market.
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Down syndrome: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Down syndrome in 2016
2.2. Total Market Share (%) Distribution of Down syndrome in 2027

3. Down syndrome: Disease Background and Overview
3.1. Introduction
3.2. Types of Down syndrome
3.3. Etiopathogenesis
3.4. Phenotypic Variability of Down syndrome
3.5. Metabolic Imbalance in Down syndrome
3.6. Clinical Conditions Associated with Down syndrome
3.7. Symptoms of Down syndrome
3.8. Risk factors for Down syndrome
3.9. Genetics Basis of Down syndrome
3.9.1. Gene expression variation
3.10. Diagnosis of Down syndrome

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Diagnosed Prevalent Population of Down syndrome in 7MM

5. Country Wise-Epidemiology of Down syndrome
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Total Diagnosed Prevalent Cases of Down syndrome in the United States
5.1.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in the United States
5.1.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in the United States
5.1.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in the United States
5.1.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the United States
5.2. EU5 Countries
5.3. Germany
5.3.1. Assumptions and Rationale
5.3.2. Total Diagnosed Prevalent Cases of Down syndrome in Germany
5.3.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Germany
5.3.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Germany
5.3.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Germany
5.3.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Germany

6. France
6.1.1. Assumptions and Rationale
6.1.2. Total Diagnosed Prevalent Cases of Down syndrome in France
6.1.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in France
6.1.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in France
6.1.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in France
6.1.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in France
6.2. Italy
6.2.1. Assumptions and Rationale
6.2.2. Total Diagnosed Prevalent Cases of Down syndrome in Italy
6.2.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Italy
6.2.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Italy
6.2.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Italy
6.2.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Italy
6.3. Spain
6.3.1. Assumptions and Rationale
6.3.2. Total Diagnosed Prevalent Cases of Down syndrome in Spain
6.3.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Spain
6.3.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Spain
6.3.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Spain
6.3.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Spain
6.4. United Kingdom
6.4.1. Assumptions and Rationale
6.4.2. Total Diagnosed Prevalent Cases of Down syndrome in the UK
6.4.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in the UK
6.4.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in the UK
6.4.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in the UK
6.4.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in the UK
6.5. Japan
6.5.1. Assumptions and Rationale
6.5.2. Total Diagnosed Prevalent Cases of Down syndrome in Japan
6.5.3. Type-Specific Diagnosed Prevalent Population of Down syndrome in Japan
6.5.4. Sex-Specific Diagnosed Prevalent Population of Down syndrome in Japan
6.5.5. Age-Specific Diagnosed Prevalent Population of Down syndrome in Japan
6.5.6. Diagnosed Prevalent Population of Down syndrome by Clinical Manifestation in Japan

7. Market Drivers

8. Market Barriers

9. Appendix
9.1. Report Methodology

10. The Publisher's Capabilities

11. Disclaimer

12. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll